386 related articles for article (PubMed ID: 32679150)
21. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
Li SR; Tang ZJ; Li ZH; Liu X
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1021-1026. PubMed ID: 32285293
[TBL] [Abstract][Full Text] [Related]
22. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
23. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
24. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
Sternberg A; McKee DL; Naujokat C
Curr Top Med Chem; 2020; 20(16):1423-1433. PubMed ID: 32416679
[TBL] [Abstract][Full Text] [Related]
25. In Silico Discovery of Candidate Drugs against Covid-19.
Cava C; Bertoli G; Castiglioni I
Viruses; 2020 Apr; 12(4):. PubMed ID: 32268515
[TBL] [Abstract][Full Text] [Related]
26. Can beta-adrenergic blockers be used in the treatment of COVID-19?
Vasanthakumar N
Med Hypotheses; 2020 Sep; 142():109809. PubMed ID: 32388480
[No Abstract] [Full Text] [Related]
27. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
28. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.
Greco A; Buccheri S; D'Arrigo P; Calderone D; Agnello F; Monte M; Milluzzo RP; Franchina AG; Ingala S; Capodanno D
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):335-337. PubMed ID: 32671399
[No Abstract] [Full Text] [Related]
30. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
31. Targeting Proteases for Treating COVID-19.
Luan B; Huynh T; Cheng X; Lan G; Wang HR
J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
[TBL] [Abstract][Full Text] [Related]
32. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
33. Co-Expression of Mitochondrial Genes and ACE2 in Cornea Involved in COVID-19.
Yuan J; Fan D; Xue Z; Qu J; Su J
Invest Ophthalmol Vis Sci; 2020 Oct; 61(12):13. PubMed ID: 33049061
[TBL] [Abstract][Full Text] [Related]
34. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells.
Stelzig KE; Canepa-Escaro F; Schiliro M; Berdnikovs S; Prakash YS; Chiarella SE
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1280-L1281. PubMed ID: 32432918
[TBL] [Abstract][Full Text] [Related]
35. Ig-like ACE2 protein therapeutics: A revival in development during the COVID-19 pandemic.
Qian K; Hu S
MAbs; 2020; 12(1):e1782600. PubMed ID: 32546047
[TBL] [Abstract][Full Text] [Related]
36. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.
Tao Q; Du J; Li X; Zeng J; Tan B; Xu J; Lin W; Chen XL
Drug Dev Ind Pharm; 2020 Aug; 46(8):1345-1353. PubMed ID: 32643448
[TBL] [Abstract][Full Text] [Related]
37. ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Sharma RK; Stevens BR; Obukhov AG; Grant MB; Oudit GY; Li Q; Richards EM; Pepine CJ; Raizada MK
Hypertension; 2020 Sep; 76(3):651-661. PubMed ID: 32783758
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2 & Covid-19: Key-Roles of the 'Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments.
Cao Z; Wu Y; Faucon E; Sabatier JM
Infect Disord Drug Targets; 2020; 20(3):348-349. PubMed ID: 32370727
[No Abstract] [Full Text] [Related]
39. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
40. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.
Gao LQ; Xu J; Chen SD
Chin J Integr Med; 2020 Jul; 26(7):527-532. PubMed ID: 32632717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
